Introduction
An explosion of patients with end-stage renal disease (ESRD) has occurred throughout the world. In Japan, the incidence of chronic renal failure has been increasing during the last two decades. Thirty thousand ESRD patients were introduced to chronic dialysis therapy in 1999 and the total number of chronic dialysis patients exceeded 200 000 during 2000 w1x. In the United States in 1996, the prevalence of ESRD was 283 000 and the incidence of ESRD was 73 000 patients per year w2x. In contrast to ESRD, the incidence of mortal cardiovascular diseases such as ischaemic heart disease and stroke has been in decline over the last 15 years. This fact implies that we have no effective strategy to halt the progression of renal diseases. Prevention and successful treatments of progressive renal diseases are highly desirable and the development of innovative therapies to halt renal diseases is crucial for reducing the number of dialysis patients, and in turn the medical expense, which has cost $10 billion in Japan.
One of the most promising therapies is gene therapy. Gene therapy has a distinct potential to treat renal disease at the most fundamental level. By the end of 1998, 3089 patients had been treated with gene therapy according to 367 protocols. However, most of these methods seem to have failed in treating diseases. Some protocols against malignancies may inhibit the growth of certain cancer types, but it cannot be concluded that gene therapy can treat all cancers. It should be pointed out that the application of human gene therapy has principally been limited to incurable diseases, such as life-threatening malignancies and HIV infection. However, the main reasons for the failures result from technical problems such as imperfection of vectors, dif®culties in gene delivery, and shutdown of transgene expression after successful gene transfer. Several approaches regarding gene transfer to the kidney exist at the experimental level w3±6x. I review here recent strategies of gene transfer into the kidney and discuss the potential application of gene therapy to renal diseases in the future.
Strategy of gene transfer to the kidney
The reported approaches of gene transfer to the kidney are listed in Table 1 .
In vivo gene transfer to the kidney
Viral vectors
Retroviral vector. Retroviruses have been employed in )50% of clinical trials, but only few reports are available on the application of kidney-targeted gene transfer. The major disadvantage of the retrovirus vector is the prerequisite for the replication of the target cells to integrate into the host genome. Since many target cells in the kidneys are non-dividing and terminally differentiated, retroviral vector-based gene transfer systems have restricted their use almost entirely to ex vivo applications to bone marrow derived cells.
The direct retroviral gene transfer to the proximal tubule was reported by Bosch et al. w7x. Rats were pretreated with folic acid to induce proliferation of the proximal tubule, and then retroviral vector was injected into the renal artery. Weak expression was detected in the proximal tubule.
Adenoviral vectors.
The adenoviral vector has distinct advantages such as high titres and the highest level of transgene expression among all available vectors. The adenoviral vector has a signi®cant advantage in delivering relatively large genes (up to 10 kb) into quiescent or terminally differentiated cells, since this virus can infect both dividing and non-dividing cells. However, the expression of the transfected gene is limited to weeks or months because the adenovirus does not integrate into the host cell genome. A crucial problem of adenoviral gene transfer is that it elicits immunological responses. The host response consists of an initial non-speci®c in¯ammation followed by speci®c cellular and humoral immune responses directed at the cytotoxic T lymphocyte (CTL)-mediated clearance of the recipient cells w8x. In fact, the death of a patient treated by adenoviral vector, from which the viral genes related to cytotoxicity and immune response are supposed to be eliminated, invokes serious dif®culties in the clinical application of gene therapy w9x. This toxicological feature of the adenovirus must be improved. Some reports exist regarding adenovirus-mediated in vivo gene transfer to the kidney. Moullier et al. observed very weak and patchy expression of the reporter gene in the proximal tubule when the adenoviral vector was injected into the renal artery. The expression lasted for 2 weeks. The retrograde approach from renal pelvis caused intense expression of the reporter gene in the papilla and medulla. In contrast, Heikkila et al. w10x demonstrated intense and diffuse gene expression in glomeruli. They perfused the solution containing the adenoviral vector for 2 h. Four days later, the expression of reporter gene was observed in 75% of the glomeruli and lasted for 4 weeks. Interestingly, they did not ®nd reporter gene expression in tubular cells and glomerular parietal epithelial cells. The adenovirus perfusion system allows selective gene transfer, targeting the glomerulus with high ef®cacy. Information concerning the immunoreaction to the adenovirus vector is lacking in these reports.
Adeno-associated virus (AAV) vector. Recombinant AAV has emerged as an attractive alternative to 
Non-viral vectors
Direct intravenous injection. Intravenously injected oligonucleotides (ODN) accumulate in the proximal tubule by phagocytosis. Rappaport et al. w15x studied the fate of 32 P-labelled ODN after intravenous injection. The labelled ODN were localized predominantly in the proximal tubule of kidney and liver within 30 min of injection. Oberbauer et al. w16x also reported that intravenously injected ODN did not merely accumulate in the brush border or lysosomal compartment in proximal tubular cells, implying that they were not totally destroyed after being phagocytosed by the proximal tubule cells. These results suggest that the renal proximal tubule is a good target of antisense therapy.
Liposome-mediated gene transfer. Lien and Lan w17x reported that the DOTMA:DOPE±DNA complex is successfully transferred into the tubular cells by intra-renal artery injection as well as by renal pelvic injection in mice. They observed tubular expression of the reporter gene mainly in the outer medulla for 6 weeks after intra-renal pelvic injection. However, the expression in the inner medulla is weak and there was no expression in the glomerular, vascular or interstitial components. A shortcoming of the HVJ-liposome method is its low transfection ef®ciency. To overcome this limitation, Saeki and Kaneda generated a new liposome in which the lipid composition mimics the viral envelope, and named this the arti®cial viral envelope (AVE) w22x. The AVE-type HVJ-liposome provides a 6-to 10-fold higher transfection ef®ciency than the conventional HVJ-liposome method. Recently, Tsujie et al. w23x demonstrated successful gene transfer into the interstitial ®broblast in the kidney after ureteral injection of AVE-type HVJ-liposome DNA complex. Expression of the Lac Z gene persists for 14 days in tubulointerstitial ®broblasts in rat kidney. In addition, in order to achieve sustained gene expression, we utilized Epstein±Barr virus (EBV) replicon apparatus w24x. EBV has been analysed thoroughly in terms of its latent infection, which is characterized by autonomous replication and nuclear retention of the EBV genome in host cells w25x. Both the cis-acting oriP (the latent viral DNA origin) sequence and the trans-acting Epstein±Barr virus nuclear antigen-1 (EBNA-1) are required for EBV latent infection. The insertion of the sequences of EBNA-1 and oriP into the plasmid resulted in sustained expression of the reporter gene in the glomeruli for at least 56 days. The two improvements made the HVJ-liposome method a more powerful and promising technique in kidney targeting gene transfer w26x.
Electroporation. Electroporation is a method for introducing a foreign gene into cells by making a pore in the membrane by electric pulse. The membrane becomes extremely conductive and the current lines pass through the inside of the cell according to the increase in ®eld strength. Consequently, pore formation by electrical breakdown, electroporation, is accomplished. Pore formation is a very rapid event, occurring within 10 ns w27x. The size of the electric pore was estimated to be -10 nm in diameter w28,29x. With increasing length of the electric ®eld the number of pores increase and they merge. When the pores merge into one large pore, irreversible breakdown occurs. Theoretically, if the molecule is smaller than the pore size, as is the case with oligonucleotides and chemical compounds, they can be transferred into the cytosol of the cells by diffusion. It is suggested that in case of a large section of DNA ()150 kb), the attachment of DNA to the cell membrane is a prerequisite for transfection by electroporation w30x.
Electroporation has been applied to gene transfer in vivo since 1991. However, the in vivo molecular mechanism leading to the pore formation following electrical breakdown is unclear. In vivo electroporation can be achieved locally by insertion of electrodes into the tissue or by holding the tissue with platetype electrodes. A relevant clinical application, electrochemotherapy, is being pursued in oncology, by using cell electropermeabilization to allow the entry of hydrophilic anti-cancer agents into the cells w31x. Short (-100 ms) and high electric pulses (250 V) were used for electrochemotherapy and this approach resulted in a drastically increased anti-tumour effect of bleomycin. Titomirov et al. w32x ®rst transfected DNA to skin by electroporation. Several reports were published to prove the ef®cacy and reproducibility of in vivo electroporation in various tissues. Among them, skeletal muscle targeting gene transfer has been studied extensively w33±36x. Most of the studies were performed by using electric pulses with short (100±300 ms) duration at 100±400 V, and the transgene product was detectable in the serum for 9 months at most w33x. Skin w32,37x, liver w38,39x, testis w40x and solid tumours w41,42x can be transfected by electroporation with similar electric ®eld conditions.
We studied the possibility of transferring a foreign gene into the kidney by electroporation. First, we selectively infused¯uorescein isothiocyanate (FITC)-labelled ODNs into the left renal artery, and clamped the left renal vein immediately after infusion. Thereafter, the left kidney was electroporated between a pair of tweezer-type electrodes. Although the electrodes did not cover the overall surface of the kidney, FITC-labelled ODNs were diffusely present in all glomeruli, including the upper or lower pole in the transfected left kidneys. To con®rm the transgene expression by gene electrotransfer, X-gal staining was performed on isolated glomeruli 4 days after transfer of LacZ gene expression vector. b-Galactosidase expression was observed in 75% of the glomeruli w43x. The luciferase activity tended to be increased in proportion to the voltage. There was no histological damage in the glomerular and tubular epithelial cells by electric pulses, even at 100 V. The electroporation-mediated gene transfer technique resulted in a 10-fold higher glomerular luciferase activity than the HVJ liposome method w43x. Thus, in vivo gene electrotransfer for targeting kidney is an effective method for gene transfer and can provide a new technique for kidney-targeting gene therapy.
Ex vivo gene transfer
The ex vivo gene transfer approach has the merit of avoiding contamination of transfection accessories such as viral proteins or chemicals.
Transfusion of genetically modi®ed cells
Two strategies have been reported on glomerular targeted ex vivo gene transfer. Extensive work on ex vivo gene transfer using the mesangial cell vector system has been done by Kitamura et al. w44,45x. Cells from an established mesangial cell line, continuously expressing the transfected foreign gene, were injected into the renal artery. The mesangial cells were trapped in the capillaries of the glomeruli and the expression of the exogenous gene was observed in the glomeruli for 4 weeks. This mesangial cell vector system provides a strong and long-term expression of the transfected genes in vivo. However, the transplanted mesangial cells did not migrate into the original mesangial area, but remained in the endocapillary lumen.
Kitamura and Suto w45x modi®ed monocytesu macrophages by retroviral vector-mediated gene transfer. They injected genetically engineered macrophages into the renal artery of lipopolysaccharidetreated rats. Soon after the injection, they isolated glomeruli and observed accumulation of the macrophages in the glomeruli. Yokoo et al. w46x also reported a similar gene delivery system to in¯amed tissues. Bone marrow cells of DBAu2 mice were differentiated to mononuclear cells, expressing CD11b and CD18. They then injected the developed mononuclear cells into the intraperitoneal cavity. The cells accumulated in the glomeruli of the mice treated with lipopolysaccharide. They applied the mononuclear cells as a vector of the glucoserebrocidase (GC) gene and injected them intraperitoneally. Consequently, the GC activity increased 3.2-fold in isolated glomeruli, suggesting that site-speci®c gene delivery in in¯amed glomeruli is feasible. Implantation of genetically modi®ed tubular epithelial cells (TECs) into the subcapsular region has been reported w47,48x. The transplanted TECs remained localized under the renal capsule and the transferred gene maintained its expression for at least 4 weeks. The authors applied this modi®ed TEC as a vehicle to deliver a particular cytokine.
Transplanted kidney
The transplanted kidney could be a good target for gene transfer. Zeigler et al. w49x reported the ®rst trial of ex vivo gene transfer into the isolated human kidney under the conditions of organ preservation. They used an adenovirus polylysine DNA complex and pulsatile perfusion for 2 h at 4 8C. A signi®cant fraction of the gene expression was localized in the proximal tubular epithelial cells. Heikkla et al. perfused isolated pig kidneys with a solution containing adenovirus. The perfusion of the adenovirus vector in the renal artery for 12 h resulted in an intense expression of the reporter gene in 85% of the glomeruli w10x.
Gene therapy for experimental renal diseases
In vivo gene therapy of glomerular diseases 
Transcription factor decoy
A novel gene therapy strategy using a transcription factor decoy has been reported by Morishita et al. w53x. Double-stranded ODN containing a cis-element for a particular transcription factor acts as a`decoy' to dissociate competitively the transcription factor from the endogenous cis-element. Consequently, the expression of particular genes is inhibited. Decoy strategies have some advantages in comparison to antisense strategy: (i) double stranded DNA is more stable; (ii) a single decoy can suppress multiple genes coding the same cis-element in the promoter region; and (iii) a decoy can inhibit the constitutively expressing factor. At the experimental level, two reports have been published on the inhibitory effects of the progression of Thy-1 glomerulonephritis. Both the E2F decoy w54x and the NFkB decoy w55,56x successfully inhibited mesangial cell proliferation and glomerular matrix expansion in experimental glomerulonephritis.
Macrophage vector system
Yokoo et al. w57x described a new strategy of gene therapy by employing bone marrow-derived monocytes harbouring the IL-1 receptor antagonist (IL-1ra). They injected the monocyte expressing IL-1ra into the intraperitoneal space. The modi®ed monocytes, expressing intercellular adhesion molecule 1 (ICAM-1) ligands CD11b and CD18, accumulated in the in¯ammatory glomeruli of anti-GBM glomerulonephritis in mice. Consequently, renal function was ameliorated and the pathological changes of the experimental glomerulonephritis were reduced by the treatment. They concluded that the lesions of acute glomerulonephritis are effectively suppressed by this prophylactic intervention.
In vivo gene therapy of tubular disorder A single injection of the antisense ODN against NauPi cotransporter inhibited both mRNA and the protein for the NauPi cotransporter, and suppressed phosphate uptake into brush border membrane vesicles of the proximal tubule. Antisense ODN has the potential to treat a variety of renal diseases, particularly proximal tubule disorders; however, the short-term effects are a reason for concern.
Cationic liposome (DOTMA:DOPE)uplasmid complex
Lai et al. w60x tried to manipulate by gene therapy the carbonic anhydrase II (CAII) de®ciency mouse with renal tubular acidosis. They treated the CAII-de®cient mouse with cationic liposome complex containing human CAII gene by retrograde injection via renal pelvis. CAII expression peaked at day 3 and decreased thereafter, but was still detectable at 1 month. The ability to acidify the urine persisted for 3 weeks. These results illustrate the potential of gene therapy as a novel treatment for hereditary renal tubular acidosis. However, the gene expression of CAII was patchy, suggesting that the effects of gene transfer may be limited.
Adenovirus vector
Yang et al. w61x injected adenovirus vector encoding aquaporin-1 cDNA into the tail vein of an aquaporin-1-null mouse. The expression of aquaporin-1 was observed in the liver and proximal tubule cells of kidney. The water permeability of the apical membrane was increased and urinary concentration defect was partially corrected in the null mouse, which had gained aquaporin-1.
Strategies of gene therapy targeting interstitial cells
Tubulointerstitial in¯ammation and ®brosis are common features in a variety of renal diseases. This in¯ammation may predict renal function and longterm prognosis more accurately than glomerular injury w62,63x. Fibrotic structural alterations of the tubulointerstitial compartment occur in virtually all progressive renal diseases. Interstitial ®brosis is characterized by accumulation of matrix proteins in the renal tubulointerstitial compartment. The mechanisms underlying the progression of interstitial ®brosis are not well understood, but this accumulation of matrix is accompanied by in®ltrating macrophages and an increased number of activated ®broblasts in the interstitium w64x.
Because the pathogenesis of tubulointerstitial ®b-rosis shares certain key mechanisms, targeting the interstitial expression of TGF-b1 should be able to prevent progression of interstitial ®brosis w65x. Targeting interstitial cells has proven to be challenging because no effective vehicle has been available to introduce the genetic material into interstitial ®bro-blasts. We recently developed an interstitial ®broblast targeting gene transfer technique using the AVE-type HVJ-liposome method. LacZ gene expression was mainly observed in ®broblasts in the tubulointerstitial space for 2 weeks after the LacZ expression vector was injected in the ureter w23x. We applied the technique for the gene therapy of experimental renal ®brosis to a prophylactic protocol. The antisense ODNs for TGF-b1 by the AVE-type HVJ-liposome method were injected into the ureter in the unilateral ureteral obstruction (UUO) rat model w66x. UUO induces acute tubulointerstitial ®brosis with macrophage in®ltration. However, introduction of antisense ODN for TGF-b1 into the renal interstitial ®broblasts inhibited interstitial TGF-b1 expression and prevented interstitial ®brosis. These ®ndings indicate that the introduction of TGF-b1 antisense ODNs into interstitial ®broblasts may be a potential therapeutic intervention for interstitial ®brosis.
Skeletal muscle-targeting gene therapy in kidney disease
Simple naked DNA transfection
Delivery of heterologous genes to skeletal muscle has been attempted since 1990. Wolff et al. ®rst injected plasmids encoding reporter genes for chloramphenicol acetyltransferase, luciferase and b-galactosidase separately into mouse skeletal muscle to estimate the ef®ciency of gene expression w67x. The expression of the luciferase gene, which was driven by the Raus sarcoma virus promoter, persisted for at least 2 months. Thereafter, similar observations have been published using expression vectors encoding secreted proteins, e.g. erythropoietin w68x, vascular epithelial growth factor (VEGF) w69x and endostatin w70x. Generally, a large amount of naked plasmid is required for gene expression in skeletal muscle and expression increases in a manner dependent on the dose of plasmid administered. Regenerating muscle increases the uptake of the plasmid DNA and improves the transfection ef®ciency. Tokui et al. pretreated the muscle with bupivacine 2 days before to induce muscle regeneration and then observed enhanced expression of the transgene w71x.
The HVJ-liposome method
The HVJ-liposome method has been used for skeletal muscle-targeting gene transfer. The HVJ-liposomemediated gene transfer into skeletal muscle results in 10 times higher gene expression compared with the simple naked plasmid injection. Isaka et al. proved that the reduction of overexpressed TGF-b ameliorates the ECM expansion of anti-Thy1 glomerulonephritis. They used a proteoglycan, decorin w72x, and a soluble receptor for TGF-b, which is composed of the extracellular domain of TGF-b type II receptor and IgG-Fc (TGF-RIIuFc) w73x. Decorin and the soluble receptor TGF-RIIuFc bind to active TGF-b, resulting in its inactivation. Decorin was generated in skeletal muscle where a plasmid encoding decorin cDNA was transfected and accumulation of the decorin was seen in glomeruli. The same behaviour was also observed in the transfection of TGF-RIIuFc. Interestingly, the increase of ECM was reduced, comparable to the decrease of TGF-b mRNA. These results suggest that manipulation of overexpressed TGF-b by skeletal muscle-targeting gene therapy may ameliorate the progression of glomerulonephritis.
AAV vector
AAV vector was used for skeletal muscle-targeting gene transfer. Skeletal muscle is a good target for the long-term gene expression of AAV. Kessler et al. w74x demonstrated that the sustained expression of the erythropoietin gene lasted for 32 weeks after single intramuscular injection of the AAV vector. During this time period, the serum level of erythropoietin increased up to 700 mUuml and the haematocrit was sustained over 80%. Gene therapy transferring AAV vectors into skeletal muscle may be promising for the constant provision of individual proteins through circulation.
Electroporation
Mesangial cell proliferation and phenotypic alterations occur in an early phase of glomerular injury and precede the increased ECM accumulation. A pivotal growth factor responsible for mesangial proliferation is platelet-derived growth factor (PDGF), which is a potent mitogen. We generated a chimeric cDNA encoding an extracellular domain of the b-PDGF receptor fused with IgG-Fc, termed PDGFRuFc, and examined the feasibility of gene therapy targeting PDGF using PDGFRuFc w75x. The chimeric PDGFRuFc molecule completely inhibited the tyrosine phosphorylation of b-PDGF receptors and the cellular proliferation induced by PDGF in vitro. We then introduced the PDGFRuFc expression vector into the muscle of nephritic rats by electroporation. The chimeric PDGFRuFc concentration in plasma was ;200 nguml 4 days after transfection. On day 5, PDGFRuFc gene transfer signi®cantly reduced the number of PCNA-positive cells and glomerular cell numbers. Northern blot analysis demonstrated that glomerular mRNA levels of aSMA, TGF-b1 and type I collagen were also suppressed by the PDGFRuFc transfection. We also observed a signi®cant reduction in matrix score in the transfected nephritic rats. These results suggest that gene therapy, by the manipulation of PDGF action using electroporation-mediated PDGFRuFc gene transfer to the skeletal muscle, might be a useful therapy for mesangioproliferative glomerulonephritis.
A similar approach can be used in an experimental mouse model of lupus nephritis. Lawson et al. reported that muscle targeting gene therapy by plasmid encoding a soluble receptor for IFNc, IFNcRuFc, signi®cantly reduced the serum level of IFNc and the disease activity, including lupus nephritis w76x. Gene transfer of the soluble cytokine receptor may be applicable for human gene therapy using skeletal muscle.
Future perspectives and conclusions
Although gene therapy has great potential in the therapy of renal diseases, it is clear that the present technology is still immature for clinical application. The improvement of the technology is indispensable. From a practical point of view, two strategies are promising for the therapy of renal diseases: skeletal muscle-targeting gene therapy and kidney transplantation.
Given that systemic delivery of the functional protein can serve as a therapy for renal diseases, skeletal muscle-targeting gene therapy is a good application. Skeletal muscle-targeting gene therapy is easy to perform, repeatable, and highly ef®cient in generating the secreting protein. At present, plasmidbased gene transfer by electroporation can generate ;100 nguml of gene product in the serum w75x. In addition, it is less expensive than administration of the puri®ed recombinant protein. The diverse characteristics of the secreting protein, e.g. inhibitor, activator or soluble receptor, can be realized by simple molecular biology techniques in the laboratory and may be directly applicable for clinical use.
The transplanted kidney is an ideal target for gene therapy, as discussed above. The feasibility of delivering therapeutic genes ex vivo has been shown to reduce the rejection rate of transplanted kidneys in an animal model. Adenoviral vector was used for the transplanted kidney approach. Swenson et al. w77x showed that Fas ligand gene transfer to the kidney protected the kidney from acute rejection and improved allograft survival in the rat. Chronic rejection can be a target for gene therapy. Tomasoni et al. w78x reported that donor-speci®c tolerance to the rat allograft was successfully induced by gene transfer with adenovirus vector coding CTLA4Ig, which is a recombinant protein competitively inhibiting the interaction between CD28 and B7. Rats who received the allograft after CTLA4Ig gene transfection survived up to 100 days, while rats who received allograft without gene transfer died within 1 week. Recently, Azuma et al. w79x reported that the ®brotic changes in the model of chronic kidney rejection can be attenuated by administration of the anti-®brotic hepatocyte growth factor. These results suggest that the prevention of early ®brosis by gene therapy is applicable in the therapy of chronic rejection. If gene transfer could be achieved by a non-viral vector, which should be relatively non-toxic and non-immunogenic, the feasibility of gene transfer to the transplanted kidney could be improved.
We believe that in the near future, innovative strategies may overcome the actual limitations of gene transfer technology and may lead to the clinical application of gene therapy in human renal diseases.
